title: The evolution of biofilms in venous access devices implanted in children with Wilms' tumour.
abstract: Biofilms form on all implanted foreign materials. In venous access ports (VAPs), the biofilm with entrapped organisms may be the source of recurring bacteraemia. At present, little is known of the development of biofilms in VAPs. In this study light, scanning, and transmission electron microscopy were used to investigate the evolution of biofilms in VAPs implanted in 15 African children with Wilms' tumour. The VAPs were removed either emergently because of infection (n = 6) or blockage (n = 3), or electively at the end of chemotherapy (n = 6). Intact biofilms were obtained from lengths of the catheter attached to ports that had been in place for 11 days to 3 years. Each was prepared for light and electron microscopy. In infected ports, shortly after implantation biofilms were thin and comprised of apparently healthy erythrocytes (RBCs) and occasional platelets, leucocytes (WBCs), and bacteria enmeshed in a network of fibrin. Three weeks after implantation, RBCs had autolysed and large numbers of WBCs and bacterial colonies were present within and on the luminal surface. In 1 instance, the lumen of a VAP had been occluded by a "plug" of WBCs. In non-infected patients, the biofilms in long-standing VAPs were of varying thickness and primarily composed of an amorphous granular material. In most cases, healthy and necrotic bacteria were present both within the core and on the surface of the biofilms. The results suggest that while bacteria, per se, are an important factor, the presence and degradation of blood components may be an equally important factor in the development of biofilms in VAP catheters.
authors.affiliation: Electron Microscope Unit, University of Durban-Westville, Private Bag X54001, Durban 4000, South Africa.
authors.forename: M A
authors.initials: MA
authors.lastname: Gregory
authors.forename: G P
authors.initials: GP
authors.lastname: Hadley
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D016470:Bacteremia / Q000209:etiology / Q000473:pathology; D001419:Bacteria / Q000302:isolation & purification / Q000648:ultrastructure*; D018407:Bacterial Physiological Phenomena; D018441:Biofilms / Q000254:growth & development; D001773:Blood Cells / Q000648:ultrastructure*; D002408:Catheters, Indwelling / Q000009:adverse effects / Q000382:microbiology; D002648:Child; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008855:Microscopy, Electron, Scanning; D016459:Prosthesis-Related Infections / Q000209:etiology / Q000473:pathology; D012008:Recurrence; D009396:Wilms Tumor / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents